RxDoctor Payments Data

Johanna Klein, MD

Internal Medicine · Brookline, MANPI 1144254053

Payments from drug & device makers

$1,198in general payments, 2019–2025

Across 59 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$401
  • Lilly USA, LLC$179
  • Novo Nordisk$139
  • Pfizer$135
  • CSL Behring$117
  • Amgen$66
  • plus $161 from 6 others

What the payments were for

  • Food & beverage$1,198100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,198 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$38,725
Medicare patients
110
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$38,229
SynthroidLevothyroxine Sodium23$4,097
Tresiba Flextouch U-100Insulin Degludec11$3,723
OxycontinOxycodone Hcl11$3,552
YuvafemEstradiol23$2,904
Atorvastatin Calcium142$1,660
Rosuvastatin Calcium48$1,455
Ezetimibe22$1,237
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$1,015
Lorazepam124$965
Albuterol Sulfate HfaAlbuterol Sulfate36$931
Venlafaxine Hcl ErVenlafaxine Hcl20$882
ValacyclovirValacyclovir Hcl28$876
Omeprazole58$808
Simvastatin42$769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$135$38,22937 claims
AbbVieSynthroid$401$4,09723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Brookline

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →